$QBIO News
Last published 3y ago
- 3y agoQBIOQ BioMed Inc. Provides Update to ShareholdersPR NewswireNEW YORK, June 23, 2023 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, provides
- 3y agoQBIOQ BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for EuropePR NewswireCompany's Liver Cancer Drug Candidate IP Portfolio strengthened Company provides operational update on strategic opportunities NEW YORK, April 14, 2023 /PRNewswire/ -- Q BioMed Inc. (OTCQB:QBIO) a biotech
- 3y agoQBIOQ BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent OfficePR NewswireUttroside B Has Shown Promising Results in Initial Pre-Clinical Testing NEW YORK, Feb. 10, 2023 /PRNewswire/ -- Q BioMed Inc. (OTCQB:QBIO) a biotech acceleration and commercial stage company focused on licensing and
- 3y agoQBIOQ BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC.PR NewswireCompany converts future royalty into 15% equity in multi-billion dollar potential product portfolio with additional $20M royalty NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Q BioMed Inc. (QBIO), a commercial stage
- 4y agoQBIOQ BIOMED PROVIDES SHAREHOLDER UPDATEPR NewswireFocus on Portfolio Monetization and Roll-up Strategy NEW YORK, Oct. 11, 2022 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to provide an update
- 4y agoQBIOQ BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKERPR NewswireGroundbreaking GDF15 biomarker may be the first single examination to accurately predict disease progression in Glaucoma The Certificate of Grant and European Patent No. 3408287 for GDF15 IN GLAUCOMA AND METHODS OF USE THEREOF NEW YORK , Sept. 27,
- 4y agoQBIOTraders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc.ACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 25, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Q BioMed. Mark had the
- 4y agoQBIOQ BioMed Inc. Provides Update to ShareholdersPR NewswireCompany Reports Revenue Improvement and Positive Data on Pipeline Assets NEW YORK, July 29, 2022 /PRNewswire/ -- Q BioMed Inc. (OTCQB:QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical as
- 4y agoQBIOQ BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancerPR NewswirePublication in Pharmaceuticals in May 2022 is titled Augmented Efficacy of Uttroside-B over Sorafenib in a Murine Model of Human Hepatocellular Carcinoma NEW YORK, July 26, 2022 /PRNewswire/ -- Q BioMed, Inc. (OTCQB:QBIO) a commercial-stage biotechnolo
- 4y agoQBIOQ BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar MarketsPR NewswireManagement's assessment and value of Q BioMed outlined NEW YORK, May 6, 2022 /PRNewswire/ -- Q BioMed, Inc. (OTCQB:QBIO) a commercial-stage biotechnology development company outlines its strategy and value proposition for its stakeholders and sharehol
- 4y agoQBIOQ BioMed announces publication of research showing augmented efficacy of its drug candidate Uttroside-B against liver cancerPR NewswireNEW YORK, March 16, 2022 /PRNewswire/ -- Q BioMed, Inc. (OTCQB:QBIO) a commercial-stage biotechnology development company announces a new publication supporting the efficacy and further development of its Uttroside B chemotherapeutic to treat liver canc
- 4y agoQBIOQ BioMed Announces Initial $500k Order of Strontium89 to Chinese MarketPR NewswireNEW YORK, March 7, 2022 /PRNewswire/ -- Q BioMed Inc. (OTCQB:QBIO), a commercial stage biotech company, announced today that it has received a confirmed $500,000 order for Strontium Chloride USP Injections under a recently inked supply contract between
- 4y agoQBIOQ BioMed Shows Significant Uptrend in Revenues in Year-End UpdatePR NewswireNEW YORK, Dec. 16, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial-stage biotech company, provides this update to shareholders with positive trend in revenues, advancement in pipeline assets and imminent uplisting to Nasdaq. The comp
- 5y agoQBIOQ BioMed Bolsters Commercialization of Strontium89 with EVERSANA PartnershipPR NewswireNEW YORK and CHICAGO, Nov. 8, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB:QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, today announced it has engag
- 5y agoQBIOQ BioMed Inc. Provides Shareholder UpdatePR NewswireNEW YORK, Oct. 25, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector is pleased to provide an update to its s
- 5y agoQBIOQ BioMed Inc. Provides Update on Strontium89 Commercial Roll Out Revenue Up in 4th Quarter with Positive TrendPR NewswireNEW YORK, Sept. 28, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, has seen an uptick in Strontium89 (Stron
- 5y agoCRVSCYDYMRNAQBIO+1Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and VariantsPR NewswirePALM BEACH, Fla., Sept. 22, 2021 /PRNewswire/ -- The U.S. government, via the American Rescue Plan, is investing more than $3 billion to accelerate the discovery, development and manufacturing of antiviral medicines as part of the government's whole-of
- 5y agoQBIOQ BioMed Inc. Updates on COVID-19 Therapeutic Development and Clinical Trials - MAN-19 therapeutic program heading to clinical trial in early 2022PR NewswireNEW YORK, Sept. 22, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a commercial stage biotechnology acceleration company, is pleased to provide an update on its partner asset MAN-19 for the treatment of Acute Respiratory Distress Syndrome (ARDS), a c
- 5y agoABVCCASIQBIOSESN+1Global Liver Cancer Therapeutics Market Size Is Forecasted To Grow To $1.148 Billion By 2026PR NewswirePALM BEACH, Fla., Aug. 24, 2021 /PRNewswire/ -- Recently, approximately 1.2 million new liver cancer cases have been reporting around the world. The increasing intense research and development activities opposing dangerous diseases have developed in the
- 5y agoQBIOQ BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent in South Korea and Shows Promising Results in Initial Pre-Clinical TestingPR NewswireNEW YORK, Aug. 24, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, asset Uttroside B – is expected to recei
- 5y agoQBIOQ BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in CanadaPR NewswireNEW YORK, Aug. 10, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has recently entered into an exclusive distribution agreement with isoSolutions Marketing & Management Inc., a well-known d
- 5y agoBETRFBNCHFCYDYEQTRF+21Proactive news headlines including Victory Square Technologies, Altamira Gold, The Parent Company, Loncor Gold and EVmoGlobeNewswireNew York , July 12, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: EVmo Inc (OTC:YAYO) closes $15M debt financing to drive
- 5y agoQBIOQ BioMed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Middle EastPR NewswireNEW YORK, July 12, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has recently entered into an exclusive license agreement with Clionix, a reputable distributor in Europe and the Middle Eas
- 5y agoABMLAURQFCLRMFENTEF+13Proactive news headlines including Aurelius Minerals, NexTech AR Solutions, American Battery Metals and Loop InsightsGlobeNewswireNew York, May 20, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: Q BioMed Inc (OTCQB:QBIO) hires contract sales force t
- 5y agoAMYZFARECBLONFBTUMF+19Proactive news headlines including Q BioMed, Dalrada Corporation, Clean Air Metals and Evergold CorpGlobeNewswireNew York , May 11, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: CO2 GRO Inc (CVE:GROW) (OTCQB:BLONF) (FRA:4021) sells
- 5y agoQBIOQ BioMed Insider to Invest up to $30M in the CompanyPR NewswireNEW YORK, May 11, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), announced today that it has signed a securities purchase agreement ("Transaction") with Aedesius Holdings Ltd (AedesiusOne), a privately owned United Kingdom based healthcare and techn
- 5y agoARECBLONFBSGMEPWCF+17Proactive news headlines including Unigold, American Resources, Loncor Resources and Falcon GoldcorpGlobeNewswireNew York, April 27, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: CO2 GRO Inc (CVE:GROW) (OTCQB:BLONF) (FRA:4021) prov
- 5y agoQBIOQ BioMed Updates ShareholdersPR NewswireNEW YORK, April 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB:QBIO), a commercial stage biotech company, updates shareholders. In March 2021,it was announced that our technology partner, Mannin Research Inc. (Mannin), is receiving up to CAD$1.7 milli